CCXI Key Statistics, Chart & Performance
The current stock price of CCXI is 51.99 USD. In the past month the price increased by 0.37%. In the past year, price increased by 50.39%.
CCXI Latest News, Press Relases and Analysis
CCXI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About CCXI
Company Profile
ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. The firm is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The firm's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. The company markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
Company Info
CHEMOCENTRYX INC
835 Industrial Road, Suite 600
San Carlos CALIFORNIA 94043 US
CEO: Thomas J. Schall
Employees: 178
Phone: 16502102900.0
CHEMOCENTRYX INC / CCXI FAQ
What does CHEMOCENTRYX INC do?
ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. The firm is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The firm's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. The company markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
Can you provide the latest stock price for CHEMOCENTRYX INC?
The current stock price of CCXI is 51.99 USD. The price increased by 0.06% in the last trading session.
What is the dividend status of CHEMOCENTRYX INC?
CCXI does not pay a dividend.
What is the ChartMill technical and fundamental rating of CCXI stock?
CCXI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting CCXI stock to perform?
13 analysts have analysed CCXI and the average price target is 53.04 USD. This implies a price increase of 2.02% is expected in the next year compared to the current price of 51.99.
Can you provide the PE ratio for CCXI stock?
CHEMOCENTRYX INC (CCXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).
Can you provide the ownership details for CCXI stock?
You can find the ownership structure of CHEMOCENTRYX INC (CCXI) on the Ownership tab.
CCXI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CCXI. When comparing the yearly performance of all stocks, CCXI is one of the better performing stocks in the market, outperforming 99.5% of all stocks.
CCXI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CCXI. While CCXI seems to be doing ok healthwise, there are quite some concerns on its profitability.
CCXI Financial Highlights
Over the last trailing twelve months CCXI reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS decreased by -6.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -357.01% | ||
| ROA | -31.74% | ||
| ROE | N/A | ||
| Debt/Equity | 0.02 |
CCXI Forecast & Estimates
13 analysts have analysed CCXI and the average price target is 53.04 USD. This implies a price increase of 2.02% is expected in the next year compared to the current price of 51.99.
For the next year, analysts expect an EPS growth of 9.69% and a revenue growth 117.77% for CCXI